The Complexity of Tumor Heterogeneity: Limitations and Challenges of the Pharmacogenomics in Cancer Treatment - Archive ouverte HAL Accéder directement au contenu
Chapitre D'ouvrage Année : 2022

The Complexity of Tumor Heterogeneity: Limitations and Challenges of the Pharmacogenomics in Cancer Treatment

Résumé

One of the most important current applications of personalized medicine is the study of the correlations between genetic variations and the emergence of tumor phenotypes in specific human groups in order to provide more personalized treatments. In particular, pharmacogenomics aims at studying the relationship between drug response and individual genomic variations. In cancer treatment, however, the overall effectiveness of this gene-based approach is impaired by the genetic and phenotypic heterogeneity of tumor cells, thus making the pharmacogenomics in cancer treatment problematic. The purpose of this paper is threefold: first, to analyze the levels of organization of tumor heterogeneity; secondly, to explore the complexity of tumor heterogeneity; finally, to estimate the epistemological and practical consequences of such a complexity for the pharmacogenomics in the personalized cancer treatment.
Fichier principal
Vignette du fichier
Militello and Bertolaso (2020) The complexity of tumor heterogeneity.pdf (206.28 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03909280 , version 1 (21-12-2022)

Identifiants

Citer

Guglielmo Militello, Marta Bertolaso. The Complexity of Tumor Heterogeneity: Limitations and Challenges of the Pharmacogenomics in Cancer Treatment. Chiara Beneduce; Marta Bertolaso. Personalized Medicine in the Making. Philosophical Perspectives from Biology to Healthcare, 3, Springer International Publishing, pp.23-45, 2022, Human Perspectives in Health Sciences and Technology, 978-3-030-74803-6. ⟨10.1007/978-3-030-74804-3_2⟩. ⟨hal-03909280⟩

Collections

HIPHISCITECH
33 Consultations
58 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More